Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7568282 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| RO7568282 High Dose | EXPERIMENTAL | Participants will receive high dose of RO7568282. |
| RO7568282 Low Dose | EXPERIMENTAL | Participants will receive low dose of RO7568282. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive RO7568282 matching placebo. |
| Name | Type | Description |
|---|---|---|
| RO7568282 | DRUG | RO7568282 will be administered as specified in the protocol. |
| Placebo | DRUG | RO7568282 matching placebo will be administered as specified in the protocol. |
Inclusion Criteria: * Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF) * Mild cognitive impairment (MCI) or mild dementia due to AD * Able to swallow whole capsules * Body mass index (BMI) within the range of 18...
Top 20 of 30 competitors
RO7568282 is an investigational small molecule being developed by Roche Holding AG for neurological conditions. It is being studied in Alzheimer's disease and Parkinson's disease. It has not been approved by the FDA and remains in clinical development.
RO7568282 is being studied as a treatment for early symptomatic Alzheimer's disease. A Phase 2 trial, NCT07781657, is evaluating its effects and safety in adults aged 50 and older in the United States. The study is randomized, double-blind, and placebo-controlled.
RO7568282 is also being investigated for early Parkinson's disease. A Phase 1 trial, NCT07781644, is testing its effects and safety in adults aged 40 and older. That study is not yet recruiting.
RO7568282 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating the drug in Alzheimer's disease and Parkinson's disease.
RO7568282 is in Phase 2 development. The lead program is a Phase 2 trial in early symptomatic Alzheimer's disease, while the Parkinson's disease program is in Phase 1. The drug is investigational and has not been approved by the FDA.
RO7568282 is being evaluated in two registered trials. NCT07781657 is a Phase 2 study in early symptomatic Alzheimer's disease with 450 planned participants. NCT07781644 is a Phase 1 study in early Parkinson's disease with 474 planned participants. Both are not yet recruiting.